Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05014815 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT05014815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05014815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Completed
Start date
November 16, 2021
Completion date
September 4, 2024
Enrollment
272 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced, unresectable, or metastatic nonsmall cell lung cancer (nsclc), nonsmall cell lung cancer, stage iiib, nonsmall cell lung cancer, stage iv